Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia



Status:Recruiting
Healthy:No
Age Range:6 - Any
Updated:3/22/2019
Start Date:May 1, 2017
End Date:June 2023
Contact:Jill Dolgin, PharmD
Email:advocacy@agtc.com
Phone:6178435781

Use our guide to learn which trials are right for you!

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia
caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the
secondary study endpoint will be efficacy.

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
AGTC-402 administered to one eye by subretinal injection in individuals with achromatopsia
caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the
secondary study endpoint will be efficacy.

Subjects will be enrolled sequentially in four groups. Subjects in Groups 1, 2 and 3 will be
at least 18 years of age and will receive a lower, middle or higher dose of study agent.
Subjects in Group 4 will be at least 6 years of age and will receive the maximum tolerated
dose identified in Groups 1, 2 and 3.

Safety will be monitored by evaluation of ocular and non ocular adverse events and hematology
and clinical chemistry parameters. Efficacy parameters will include visual acuity, light
discomfort testing, color vision, static visual field, ERG, adaptive optics retinal imaging
and OCT.

Inclusion Criteria:

1. Retinal disease consistent with a diagnosis of achromatopsia and documented mutations
in both alleles of the CNGA3 gene;

2. At least 18 years of age for Groups 1, 2 and 3 and at least 6 years of age for Group
4;

3. Able to perform tests of visual and retinal function;

4. Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent
20/80) based on the average of two examinations at the baseline visit;

5. Acceptable laboratory parameters;

6. For females of childbearing potential: A negative pregnancy test within 2 days before
administration of study agent.

Exclusion Criteria:

1. Presence of myopia which, in the opinion of Investigator, may create increased
surgical risk for the subject in the study eye;

2. Evidence of degenerative myopia in the study eye;

3. Pre-existing eye conditions that would contribute to vision loss in either eye or
increase the risk of subretinal injection in the study eye.
We found this trial at
8
sites
Gainesville, Florida 32607
Principal Investigator: Christine N Kay, MD
Phone: 352-371-2800
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
900 Northwest 17th Street
Miami, Florida 33136
Principal Investigator: Byron L Lam, MD
Phone: 305-326-6021
?
mi
from
Miami, FL
Click here to add this to my saved trials
243 Charles St
Boston, Massachusetts 02114
(617) 523-7900
Principal Investigator: Rachel M Huckfeldt, MD, PhD
Phone: 617-573-3621
Massachusetts Eye & Ear Infirmary Whether you see our physicians at Mass. Eye and Ear's...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Cincinnati, Ohio 45242
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Jerusalem, 91120
Principal Investigator: Eyal Banin, MD, PhD
Phone: +972-2-6448917
?
mi
from
Jerusalem,
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Jessica Morgan, PhD
Phone: 215-614-4196
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Portland, Oregon 97239
Principal Investigator: Mark A Pennesi, MD, PhD
Phone: 503-494-0020
?
mi
from
Portland, OR
Click here to add this to my saved trials